RECRUITING
I'm interested ...!!
Contingency Management for Cannabis Use for Persons With HIV
The purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. Specifically, the contingency management program will provide motivational (monetary) incentives to participants who achieve biochemically verified cannabis abstinence. Over the 28-days of this pilot feasibility trial, participants will attend seven study visits. During these visits, participants will complete survey questionnaires to assess sociodemographic, psychosocial, and behavioral factors. In addition, participants will provide blood and urine specimens for testing and quantitation of HIV viral load, biomarkers of systemic inflammation and for the detection of cannabis and other drugs of abuse.
Conditions:
🦠 Marijuana 🦠 HIV Infections
🗓️ Study Start (Actual) 1 August 2021
🗓️ Primary Completion (Estimated) 1 December 2024
✅ Study Completion (Estimated) 1 June 2025
👥 Enrollment (Estimated) 45
🔬 Study Type INTERVENTIONAL
📊 Phase NA
Locations:
📍 Houston, Texas, United States
📍 San Antonio, Texas, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * HIV-positive (confirmed via HIV medication or relevant HIV labs in subject's name)
    • * Self-report of cannabis use at least once per week in the 6-month period prior to consent
    • * Provide a positive urine toxicology (UTOX) screen for cannabis
    • * Not seeking treatment for cannabis use
    • * Willing to stop using cannabis for 28 days and attend eight study visits over six weeks.
    • * Ability and willingness to provide inform consent
    • * English fluency

    Exclusion Criteria:

    • * Currently receiving treatment for cannabis or other drug use disorder
    • * Diagnosed or receiving treatment for a current major depressive or anxiety disorder
    • * Diagnosed with any current alcohol or substance use disorder (excluding nicotine) using the Structured Clinical Interview for Clinical Disorders (SCID) Interview (22)
    • * Positive UTOX screen for opioids
    • * Having a medical, psychiatric, occupational, or other condition that, in the judgment of the study physician, would make participation difficult or unsafe.
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 27 April 2021
  • First Submitted that Met QC Criteria 27 April 2021
  • First Posted 29 April 2021

Study Record Updates

  • Last Update Submitted that Met QC Criteria 11 March 2024
  • Last Update Posted 12 March 2024
  • Last Verified March 2024
I'm interested ...!!